Yes, I was not saying it wasn’t, only that it is a TLR3 Agonist. You asked if there were other suppliers of Poly ICLC, and I confirmed that is the generic name for Hiltonol, which is the brand name and it comes from Oncovir. But there are other TLR3 Agonists made by other parties and they all have patents for their way of making it, just like there are a variety of PD-L1 and PD1 blockers, made by different means. And there are likely now patents that have expired, since it has been around for 40 years. Not sure if they are all exactly the same in efficacy, as some are more water soluble. But the point further was that the drug is being studied in many places and has not proven to be efficacious so far by itself and that any manufacturer would probably love to work together. They also are using it in many vaccine applications and not just cancer, so it’s not like they have an incentive to exclude DCVax-L from having access or doing a deal with them.
News 
Market Data 
Discover 
AI
